GLP-1 before and after: what the numbers actually show at 40+

Search "GLP-1 before and after" and the internet hands you two extremes: dramatic transformation photos with no context attached, or forum threads insisting the drug "did nothing" for someone whose numbers look eerily similar to yours. Neither extreme is the trial data. The trial data is duller, more specific, and genuinely useful before you decide whether your own results are normal.

How much weight do people actually lose on a GLP-1?

The clearest, largest numbers come from the manufacturers' own randomized trials, and they're public. In STEP 1, the trial that established semaglutide (Wegovy) as a weight-loss drug, adults without diabetes lost an average of close to 15% of their starting body weight over 68 weeks on the medication, against roughly 2% on placebo. In SURMOUNT-1, tirzepatide's (Zepbound) equivalent trial, the same kind of population lost somewhere between 15% and 21%, depending on which of the three doses tested they ended up on, against about 3% on placebo.

An average hides more than it reveals, though. Researchers sort GLP-1 users into rough response bands: a minority lose less than 5% and are generally considered non-responders, most land in a moderate 5%-to-15% range, and a meaningful share — on the higher tirzepatide doses, sometimes a third of participants — cross 20% or more and get called super-responders. If your own number lands under the headline average from a press release, that doesn't mean the drug failed on you. It means you're sitting somewhere in a real distribution, not falling short of a marketing slide.

Which GLP-1 gets better results — semaglutide or tirzepatide?

This is the question most people actually came here for, and there's now a real head-to-head trial instead of two separate studies run years apart. SURMOUNT-5 put both drugs through an identical protocol in the same population — adults with obesity, no diabetes — over 72 weeks. Tirzepatide won clearly: about 20% average weight loss against about 14% for semaglutide. If a bigger number is genuinely your deciding factor between the two, tirzepatide is the better-supported pick.

That's not quite the end of the story. Semaglutide's own ceiling moved after that trial closed — a higher 7.2mg version of Wegovy, approved in 2026, reached roughly 21% average loss in a trial of its own, which narrows the gap considerably. No study has run that specific higher dose directly against tirzepatide, so treat that as semaglutide closing distance, not a proven tie. And a bigger average isn't automatically the right choice for you: tirzepatide tends to cost more, and the two drugs differ somewhat in which side effects show up most, both worth weighing with whoever is prescribing.

What does a realistic before-and-after timeline actually look like, month by month?

The scale doesn't move in a straight line, and knowing the shape of the curve ahead of time makes the slow early weeks easier to sit through. Both drugs start at a low, deliberately sub-therapeutic dose and step up roughly every four weeks — the same titration pattern covered in the GLP-1 dosage chart — so the timeline below tracks the dose climbing, not a fixed calendar.

• Weeks 1–2: Appetite is usually the first thing to shift, often before the scale shows much — food noise quiets and portions that used to feel small start feeling like enough.
• Week 4: In the STEP 1 trial, the average semaglutide user was down close to 4% of starting weight — noticeable, not yet dramatic.
• Week 12 (month 3): Average loss reached close to 10% in that same trial. This is also the checkpoint clinicians use to judge whether a GLP-1 is working — losing at least 5% by three months is the standard threshold for staying the course rather than switching drug or dose.
• Month 6: Most people are still climbing toward their dose ceiling around here, with losses commonly running through the low-to-mid teens percentage-wise depending on the drug and dose reached.
• Month 12–15 (68–72 weeks): This is where the major trials measured their headline results — roughly 15% for semaglutide, higher for tirzepatide depending on dose, as above.
• Month 18 and beyond: Loss tends to plateau rather than keep dropping. In semaglutide's two-year STEP 5 trial, the average barely moved between 68 and 104 weeks, holding within about a percentage point of where it had already landed.

Does a GLP-1 work differently if you're not diabetic?

It does — and the difference works in your favor. The trials that built the weight-loss case for semaglutide split cleanly along this line: STEP 1 enrolled adults without diabetes and produced that roughly 15% average; STEP 2, the sister trial run in adults with type 2 diabetes on the identical dose, landed closer to 10%. Same drug, same dose, same trial length — a meaningfully smaller average result in people with diabetes.

The likely explanation isn't mysterious: diabetes itself involves insulin resistance and metabolic changes that tend to blunt weight loss across nearly every intervention, not just this drug class. So if you're a non-diabetic woman starting a GLP-1, the population you most resemble in the data is the one that lost more, not less — a reassuring detail that a lot of GLP-1 coverage skips when it treats trial averages as one-size-fits-all.

How do GLP-1 drugs actually work for weight loss?

GLP-1 — glucagon-like peptide-1 — is a hormone your gut already makes after eating. These medications are GLP-1 receptor agonists, built to mimic that hormone and stay active far longer than the natural version does. That single mechanism does several things at once: it acts on appetite centers in the brain to quiet hunger and the mental static some people call food noise, it slows how quickly the stomach empties so a normal meal feels filling for longer, and it prompts the pancreas to release insulin only when blood sugar is genuinely elevated.

Tirzepatide adds a second target on top of that: it's a dual GIP/GLP-1 receptor agonist, activating a second gut hormone pathway alongside the first. That extra mechanism is the leading explanation for why tirzepatide tends to produce larger average results, though exactly how much of the gap comes from the second receptor versus the specific doses tested in each trial is still being sorted out by researchers. Either way, the appetite effect is doing most of the visible work — less hunger and earlier fullness, which is why the scale moves without anyone consciously white-knuckling a diet.

Why might your results look different in perimenopause?

This is the honest, underexplored piece — and it's actually been studied directly rather than left to theory. A 2025 analysis published in the journal Obesity went back through the tirzepatide trials and split women by reproductive stage: premenopausal, perimenopausal, and postmenopausal. Premenopausal women lost close to 26% of body weight on tirzepatide against about 2% on placebo. Perimenopausal and postmenopausal women lost about 23% against roughly 3% on placebo.

Read that gap for what it is: real, but small. A few percentage points separate a woman early in perimenopause from one who hasn't started the transition yet — not a different drug response, just a somewhat smaller one. Falling estrogen is the likely reason: it shifts fat toward the abdomen and worsens insulin sensitivity, working against the same appetite and metabolic machinery a GLP-1 is trying to help. The medication is still working in a 40-plus body. It's working against slightly more resistance.

Where hormones enter the picture more directly is hormone therapy itself — a separate decision from the GLP-1 question, not a smaller version of it. The GLP-1 and menopause guide covers how HRT and a GLP-1 compare, whether combining them helps, and which problem each one is actually solving; this page stays focused on the weight-loss numbers themselves.

What actually determines your individual results?

Averages and trial data explain the shape of the curve. They don't predict your specific number. A handful of factors reliably move the needle in real practice:

• The dose you actually reach and tolerate. SURMOUNT-1's own numbers show several points of gap between the low and high tirzepatide dose — reaching and staying on a higher maintenance dose, if your prescriber and your side effects allow it, generally means more loss.
• How consistently you take it. Missed or delayed weekly doses interrupt the steady drug level these medications depend on; consistency is a variable the trials controlled for that real life doesn't.
• Where you started. Starting weight and metabolic health shape both how much percentage loss is realistic and how your body responds along the way — that's biology, not a personal shortfall.
• Whether you hit the "working" threshold early. Clinicians generally treat at least 5% loss by three months as the sign a given drug and dose are doing their job. Falling well short of that by then is usually the point a dose change or a different drug gets discussed, not a reason to wait it out indefinitely.
• Individual variation that isn't fully explained yet. Some of the spread between minimal responders and super-responders in the trials comes down to biology researchers are still mapping — genetics and receptor sensitivity that don't show up on an intake form.

Is hitting a plateau normal, or does it mean the drug stopped working?

Normal — and the trial data backs that up directly rather than leaving it to reassurance. In STEP 5, semaglutide's two-year trial, the average participant's weight barely moved between the 68-week mark and the 104-week mark; it held within about a percentage point of where it had already landed. That's not the drug losing effectiveness. It's the body settling at a new, lower stable weight once the dose has been at its ceiling for a while — the same pattern that shows up after most successful weight-loss methods, not something unique to this drug class.

A true plateau — weight flat for many weeks on a dose you've tolerated fine for a while — is worth a conversation with your prescriber about whether your current dose is genuinely maxed out for you, not a signal to panic or assume the medication has quietly failed. What's different from a healthy plateau is weight actively climbing back up while you're still on the medication at an unchanged dose; that pattern deserves a closer look sooner rather than later.

Does the weight come back if you stop?

For most people, yes — a meaningful share of it. In the STEP 1 extension study, people who stopped semaglutide after a year regained about two-thirds of the weight they'd lost within the following year, alongside a similar reversal in the metabolic improvements the drug had produced. Tirzepatide's own withdrawal data, from the SURMOUNT-4 trial, tells a similar story: participants who stopped the drug after roughly nine months regained an average of about 14% of their body weight over the following year, while those who kept taking it lost additional weight instead.

Real-world data outside the tight structure of a trial is messier and somewhat more encouraging — some retrospective studies of insurance and health-record data find a meaningful share of patients hold onto most of their loss a year after stopping, likely reflecting people who built other habits alongside the medication or tapered rather than stopped abruptly. Still, the honest read of the evidence overall is that these drugs treat an ongoing condition, not a temporary one, the way blood-pressure medication does — stopping usually means the underlying biology reasserts itself, not that anything went wrong.

Does the number on the scale tell the whole story?

Not entirely, and this matters more the further into a GLP-1 you get. A meaningful share of what leaves the body during any fast weight loss — this drug class included — is lean muscle, not just fat, and that share tends to be a bigger deal after 40 because falling estrogen is already working against the same tissue. Two women who lose an identical percentage on the scale can end up looking, and functioning, quite differently depending on how much of that was muscle.

This page stays on the weight-loss numbers themselves; the muscle side of the story — what the body-composition data actually shows, and what protects your strength while the weight comes off — has its own dedicated guide that goes considerably deeper than a paragraph here could.

What does this cost, and where do you actually start?

Cost varies enough by drug, dose, insurance, and provider that a single figure here would be more misleading than useful. Brand-name pens carry the highest sticker price, compounded versions run considerably cheaper but sit in a shifting regulatory space, and insurance coverage depends heavily on whether your plan recognizes an obesity diagnosis at all. What's consistent is that comparing real, current pricing across providers before committing saves real money.